Update 9-08-20 Breaking News from SANUWAVE Health, Inc. (OTCQB: SNWV) Acquisition Of Celularity’s UltraMIST(R) Brings Exceptional Value, But It’s The Reimbursement Team That Can Deliver Exponential Growth
“The asset acquisition immediately brings more than $15 million in accretive revenues and roughly $4 million of EBITDA to the company’s yearly run-rate” Full Press Release – https://finance.yahoo.com/news/sanuwaves-acquisition-celularitys-ultramist-r-125400540.html
GROUND FLOOR OPPORTUNITY
We live in interesting times. Technology is coming at us like a speeding bullet, with so many innovations it can be hard to keep up. Virtually every aspect of the human experience has been impacted by technology in this 20-year-old millennium.
Perhaps the sector with the most influential and impactful innovations is biotechnology. We marvel at some of the new technologies being developed to treat diseases such as cancer, Alzheimer’s, Diabetes, Covid 19 and many others.
There are many new treatments for disease based on molecular science, genetic manipulation, new drug combinations, and new drug delivery systems.
As investors, we all would like to cash in on these developments in biotech, but too often it seems like we miss out at the beginning, the best time to get in on an up-and-coming stock. By the time we learn about a stock with a new development, or a major catalyst, it seems the value is already gone from the shares.
Keep reading, there is one you haven’t missed out on…yet.
SANUWAVE Health, Inc. (OTCQB: SNWV)
SANUWAVE is a shockwave technology company developing patented, noninvasive devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Its lead product, the dermaPACE System, is FDA Cleared for the treatment of Diabetic Foot Ulcers (DFU) in the United States.
Shockwave treatment was originally developed for the treatment of kidney stones over 30 years ago. A wealth of medical experience, state-of-the-art engineering and optimal quality have been built into the dermaPACE System, and extensive clinical studies and tests have confirmed its safety and efficacy.
The dermaPACE System is the only focused Extracorporeal Shock Wave Therapy (ESWT) cleared by the Food and Drug Administration (FDA) for the treatment of Diabetic Foot Ulcers (DFU).
“A breakthrough compared to what we’ve had so far in wound care”- Dr. Jayesh Shah, Medical Director
Northeast Baptist Wound Healing Center
The dermaPACE System is CE Marked for the application of pulsed acoustic waves on acute and chronic defects of the skin and subcutaneous soft tissues, such as:
Post-operative wound healing defects
Deep-partial thickness burns
THE dermaPACE treatment procedure:
The edges of the wound may be measured to determine the size of the wound. The wound will be gently cleansed, and sterile gel will be applied to the wound. The dermaPACE Applicator will be gently applied to the wound surface, and treatment will begin. The device makes an audible “popping” sound that will last until the treatment ends. After treatment, the patient will receive standard wound care including a dressing and other instructions from your medical professional.
The company received FDA clearance for dermaPACE® in 2017 for the treatment of diabetic foot ulcers and began to commercialize the system in January 2019.
The dermaPACE System is a new way to treat diabetic ulcers, as well as other wounds and it is being placed in more and more wound centers because it works.
The orthoPACE System
SANUWAVE has a history of treating bone conditions requiring osteogenesis, calcific joints, conditions causing painful joints, and treating chronic pain caused by musculoskeletal disorders. The orthoPACE System is the latest device offered by SANUWAVE to effectively treat these conditions. Treatment with the orthoPACE System has a proven success rate that is equal to or greater than that of surgery – usually with just one procedure and without the inherent risks, complications, and lengthy recovery time of invasive surgery. The orthoPACE System is CE cleared for use in several countries but not FDA cleared.
SANUWAVE’s patented shock wave technology was evaluated in-vitro for effects on difficult to remove biofilms created by both Gram-negative bacteria (Pseudomonas aeruginosa) and Gram-positive bacteria (Staphylococcus aureus). The results indicate that SANUWAVE’s technology can effectively remove biofilms from surfaces using only the mechanical stresses produced by the shock waves. These tests indicate that SANUWAVE’s technology could potentially reduce or eliminate the need to use chemicals, enzymes, or antibiotics to destroy and remove biofilms.
You may want to read the paragraph above again. It’s a big deal. Over time viruses and bacteria have adapted and created a biofilm to protect themselves from the drugs we’ve created to defeat them (think of the bubble of fat that protects the coronavirus). Eliminating those biofilms may lead to better results in destroying them.
Earlier this year, SNWV signed a license agreement with Nanovibronix for the manufacture and delivery of its WoundShield technology. WoundShield is an advanced therapeutic ultrasound system that is intended to accelerate wound healing by increasing blood flow and oxygenation of tissue. The system includes a portable, battery-powered electronic unit that delivers localized energy via an actuator that is applied adjacent to the wound creating a therapeutic effect without interfering with the wound dressing.
SANUWAVE has announced the filing of a patent for the use of shockwaves as a treatment for numerous respiratory conditions, including COVID-19, and has applied for additional grants to research the use of shockwaves in respiratory ailments
SANUWAVE lists nearly 100 wound care centers across the United States that are using dermaPACE in their practice. SNWV had FYE 2019 revenue of $1 million.
Everything discussed above is great news. SNWV has innovative medical devices and is a progressive, growing company. But is that what makes SNWV a ground floor opportunity now? Nope.
On August 10th, the company announced that it has completed the acquisition of the wound care assets of Celularity, consisting of the UltraMIST® Ultrasound Healing Therapy assets and partnership rights for Celularity’s wound care biologic products, Biovance® and Interyl®, which are excellent complements to the dermaPACE® System.
This accretive acquisition has the potential to send SNWV shares into the stratosphere. Keep reading and find out why.
The acquisition of the Celularity (a private company) assets has been in the works since June and has finally closed. The acquisition has been described as a minnow swallowing a whale as the acquired, accretive assets will immediately make SNWV a much larger company.
The acquisition is expected to be a transformative event for SANUWAVE and represents a strategically and financially growth opportunity for the company. The transaction broadens SANUWAVE’s market and combines two highly complementary energy transfer technologies with two biologic skin substitute products to create a platform of scale with an end-to-end product offering in the advanced wound care market.
Furthermore, it uniquely positions SANUWAVE to address the entire advanced wound care patient pathway from the initial stages of treatment to closure. The treatment combination of the UltraMIST® and the dermaPACE® System creates a significant opportunity to demonstrate improved patient outcomes over the current standard of care, initially for diabetic foot ulcers and across all wound indications in the future.
The UltraMIST® system delivers low frequency ultrasound to the treatment site using a non-contact fluid (e.g., saline). It produces a low energy ultrasound-generated mist used to promote wound healing.
According to the CEO of SANUWAVE, Kevin Richardson, “We’re going to go from a hundred locations to over a thousand,” adding that the company will also be expanding their sales force and the number of products in their portfolio. “It transforms the company dramatically.”
The UltraMIST® system is already approved in the U.S. for all acute and chronic wound indications and is currently used in hospitals, wound care centers, and nursing homes across the US. The UltraMIST® device is already established in over 900 wound care clinics and provides SANUWAVE with a strong reoccurring revenue stream from accessory sales.
Additionally, capital expenditures to penetrate new markets is expected to be low, resulting in a free cash flow conversion of 95-98% from each new placement.
As part of the asset acquisition SNWV will be a partner in Celularity’s innovative approach to cell therapy which harnesses the unique therapeutic potential locked within the cells of the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placental-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. In addition, Celularity manufactures and markets two commercial-stage products, Biovance® Human Amniotic Membrane Allograft and Interfyl® Human Connective Tissue Matrix.
Biovance and Interfyl may be the products that propel SNWV shares in the mid to long term. The cellular level matrix provided by these products may regrow tissue impacted by surgery or wounds, as well as regenerating cells damaged by disease.
Yes, you read that right. SNWV now has a partnership with Celularity to advance stem cells for the replacement of skin and other human tissue.
On July 1, 2020, The Stock Day Podcast interviewed CEO of the company, Kevin Richardson, regarding the pending acquisition of the Celularity assets, and how it would impact SANUWAVE. The interview is linked below:
CEO Kevin Richardson shared that “the acquisition will bring the Company closer to up listing to the NASDAQ and will help with their international expansion.”
The value opportunity that may drive investor interest in SANUWAVE is that its new comprehensive wound care platform may earn a place as an industry-leading wound care treatment provider from discovery to closure, and they may be the only company able to make that claim.
Wound care is a $10 billion market.
Now, with access to dermaPACE®, UltraMIST®, Biovance®, Interfyl®, and WoundShield®, SANUWAVE can administer all five therapies at different stages of the healing process. The ultimate result will lead to an overall better closure of the wound.
SANUWAVE also presents with a portfolio of potential verticals that far exceeds what they had before the asset acquisition.
You are reading this today, so you are an early bird in the new SNWV story, but that won’t last for long. Soon everyone will know about the new developments at SANUWAVE because listed below are the conferences the company will present at in September.
The LD Micro 500
Dates: September 1 – 4, 2020
The Global Chinese Financial Forum-Investing in Innovation
Dates: September 10, 2020
HC Wainwright 22nd Annual Global Investment Conference
Dates: September 15-16, 2020
Lake Street Capital Markets 4th Annual Best Ideas Growth Conference (Big 4)Dates: September 17, 2020
The acquisition of the Celularity assets could transform SANUWAVE into a major player in the massive wound care market, create a potential up list to the NASDAQ, while increasing the company revenues dramatically. Don’t hesitate, do your due diligence, but don’t wait too long.
The Traders News Group
Do we disclose any information to outside parties?
We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address
What do we use your information for?
When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. TNS LLC’s parent company has been compensated twenty six thousand dollars cash via bank wire by Hart Associates Inc. for three weeks coverage of SNWV beginning on 9-3-20. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.